Meeting
2014 ASCO Annual Meeting
A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Authors
Nathan Hale Fowler
The University of Texas MD Anderson Cancer Center, Houston, TX
Nathan Hale Fowler , Wolfgang Hiddemann , John Leonard , Esther Rose , Tahamtan Ahmadi , Jessica Vermeulen , Julie S. Larsen , Steven Sun , Lisa Mentzer , Shean-Sheng Wang , Tzu-Min Yeh , Gilles A. Salles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01974440
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8611^)
DOI
10.1200/jco.2014.32.15_suppl.tps8611
Abstract #
TPS8611^
Poster Bd #
298A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
First Author: Nathan Hale Fowler
Poster
2023 ASCO Annual Meeting
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
First Author: Laurie Helen Sehn
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin
Poster
2021 ASCO Annual Meeting
ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
First Author: Laurie Helen Sehn